Alto Neuroscience Faces Securities Fraud Lawsuit with Schall Law Firm

Alto Neuroscience is facing a class action lawsuit for alleged securities fraud. The company is accused of misrepresenting the effectiveness of its drug ALTO-100 for major depressive disorder and overstating its business and financial prospects. Investors who purchased securities between February 2, 2024, and October 22, 2024, may be eligible to recover losses. The Schall Law Firm is representing investors in the lawsuit.

Alto Neuroscience, Inc. (NYSE: ANRO) is facing a class action lawsuit filed by The Schall Law Firm, alleging violations of federal securities laws. The lawsuit, which was announced on September 2, 2025, accuses the company of making false and misleading statements regarding the effectiveness of its drug ALTO-100 for major depressive disorder (MDD) and overstating its business and financial prospects [1].

The class action lawsuit includes investors who purchased Alto Neuroscience's securities during the period from February 2, 2024, to October 22, 2024. Investors are encouraged to contact the Schall Law Firm to discuss their rights and potential eligibility to recover losses. The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation [1].

According to the Complaint, Alto Neuroscience led investors to believe that ALTO-100 was more effective in treating MDD than it actually was. The company is accused of overstating its business and financial prospects, which resulted in investors suffering damages when the market learned the truth about Alto Neuroscience [1].

The Major Depressive Disorder (MDD) market is expected to grow significantly due to advancements in research, supportive regulations, and growing awareness. The market size was approximately USD 7,165 million in 2023 and is projected to grow at a CAGR of 4.8% through 2034 [2]. Despite the growth prospects, the lawsuit highlights the importance of accurate and transparent financial reporting for public companies.

Investors should closely monitor the developments in this lawsuit and consider consulting with legal or financial professionals to understand their rights and potential impact on their investments. The Schall Law Firm can be reached at 310-301-3335 or via their website at www.schallfirm.com [1].

References:
[1] https://www.prnewswire.com/news-releases/anro-investors-have-opportunity-to-lead-alto-neuroscience-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302543390.html
[2] https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/34486058/major-depressive-disorder-market-outlook-2034-clinical-trials-market-size-medication-prevalence-companies-by-delveinsight/